VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer

Journal of Experimental Medicine

Volumn 207, Issue 13, 2010, Pages 2855-2868

  Waldner, Maximilian J ^a,b   Wirtz, Stefan ^a,b   Jefremow, André ^b   Warntjen, Moritz ^b   Neufert, Clemens ^a   Atreya, Raja ^a   Becker, Christoph ^a,b   Weigmann, Benno ^a,b   Vieth, Michael ^c   Rose John, Stefan ^d   Neurath, Markus F ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c INSTITUTE OF PATHOLOGY   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; INTERLEUKIN 6; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLITIS; COLITIS ASSOCIATED CANCER; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; COLITIS; COLONIC NEOPLASMS; DEXTRAN SULFATE; ENDOTHELIAL CELLS; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78650407055     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20100438     Document Type: Article

References (52)

1. Avraamides, C.J., B. Garmy-Susini, and J.A. Varner. 2008. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer. 8:604-617. doi:10.1038/nrc2353
2. Baish, J.W., and R.K. Jain. 1998. Cancer, angiogenesis and fractals. Nat. Med. 4:984. doi:10.1038/1952
3. Baish, J.W., and R.K. Jain. 2000. Fractals and cancer. Cancer Res. 60: 3683-3688.
4. Balkwill, F., K.A. Charles, and A. Mantovani. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 7:211-217. doi:10.1016/j.ccr.2005.02.013 (Pubitemid 40568680)
5. Becker, C., S. Wirtz, M. Blessing, J. Pirhonen, D. Strand, O. Bechthold, J. Frick, P.R. Galle, I. Autenrieth, and M.F. Neurath. 2003. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112:693-706.
6. Becker, C., M.C. Fantini, C. Schramm, H.-A. Lehr, S. Wirtz, A. Nikolaev, J. Burg, S. Strand, R. Kiesslich, S. Huber, et al. 2004. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 21:491-501. doi:10.1016/j.immuni.2004.07.020 (Pubitemid 39370505)
7. Becker, C., M.C. Fantini, S. Wirtz, A. Nikolaev, R. Kiesslich, H.A. Lehr, P.R. Galle, and M.F. Neurath. 2005. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut. 54:950-954. doi:10.1136/gut.2004.061283 (Pubitemid 40873907)
8. Bernstein, C.N., J.F. Blanchard, E. Kliewer, and A. Wajda. 2001. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 91:854-862. doi:10.1002/1097-0142(20010215)91:4<854:: AIDCNCR1073>3.0.CO;2-Z
9. Bollrath, J., T.J. Phesse, V.A. von Burstin, T. Putoczki, M. Bennecke, T. Bateman, T. Nebelsiek, T. Lundgren-May, O. Canli, S. Schwitalla, et al. 2009. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 15:91-102. doi:10.1016/j.ccr.2009.01.002
10. Boquoi, A., R. Jover, T. Chen, M. Pennings, and G.H. Enders. 2009.Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia. Gastroenterology. 136:596-606: e4. doi:10.1053/j.gastro.2008.10.028
11. Cao, Y. 2009. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2:re1. doi:10.1126/scisignal.259re1
12. Carmeliet, P. 2003. Angiogenesis in health and disease. Nat. Med. 9:653-660. doi:10.1038/nm0603-653 (Pubitemid 36749213)
13. Chen, S.H., D.A. Murphy, W. Lassoued, G. Thurston, M.D. Feldman, and W.M. Lee. 2008. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol. Ther. 7:1994-2003.
14. Clevers, H. 2004. At the crossroads of inflammation and cancer. Cell. 118:671-674. doi:10.1016/j.cell.2004.09.005 (Pubitemid 39221727)
15. Costa, C., J. Incio, and R. Soares. 2007. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 10:149-166. doi:10.1007/s10456-007-9074-0 (Pubitemid 47305203)
16. Ellis, L.M., and D.J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer. 8:579-591. doi:10.1038/nrc2403
17. Emura, F., Y. Saito, and H. Ikematsu. 2008. Narrow-band imaging optical chromocolonoscopy: advantages and limitations. World J. Gastroenterol. 14:4867-4872. doi:10.3748/wjg.14.4867
18. Ferrara, N. 2009. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29:789-791. doi:10.1161/ATVBAHA.108.179663
19. Ferrara, N., R.D. Mass, C. Campa, and R. Kim. 2007. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58:491-504. doi:10.1146/annurev.med.58.061705.145635 (Pubitemid 46706529)
20. Fischer, M., J. Goldschmitt, C. Peschel, J.P. Brakenhoff, K.J. Kallen, A. Wollmer, J. Grötzinger, and S. Rose-John. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15:142-145. doi:10.1038/nbt0297-142
21. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186. doi:10.1056/NEJM197108122850711
22. Giatromanolaki, A., M.I. Koukourakis, E. Sivridis, G. Chlouverakis, E. Vourvouhaki, H. Turley, A.L. Harris, and K.C. Gatter. 2007. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur. J. Clin. Invest. 37:878-886. doi:10.1111/ j.1365-2362.2007.01866.x
23. Grivennikov, S., E. Karin, J. Terzic, D. Mucida, G.Y. Yu, S. Vallabhapurapu, J. Scheller, S. Rose-John, H. Cheroutre, L. Eckmann, and M. Karin. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103-113. doi:10.1016/j.ccr.2009.01.001
24. Grosios, K., J. Wood, R. Esser, A. Raychaudhuri, and J. Dawson. 2004. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. 53:133-142. doi:10.1007/s00011-003-1230-4 (Pubitemid 38526596)
25. Grothey, A., and E. Galanis. 2009. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat. Rev. Clin. Oncol. 6:507-518. doi:10.1038/nrclinonc.2009.110
26. Jain, R.K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58-62. doi:10.1126/science.1104819 (Pubitemid 40093472)
27. Jain, R.K., D.G. Duda, J.W. Clark, and J.S. Loeffler. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3:24-40. doi:10.1038/ncponc0403 (Pubitemid 43108832)
28. Kerbel, R.S. 2008. Tumor angiogenesis. N. Engl. J. Med. 358:2039-2049.doi:10.1056/NEJMra0706596 (Pubitemid 351656458)
29. Kiesslich, R., J. Burg, M. Vieth, J. Gnaendiger, M. Enders, P. Delaney, A. Polglase, W. McLaren, D. Janell, S. Thomas, et al. 2004. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology. 127:706-713. doi:10.1053/j.gastro.2004.06.050 (Pubitemid 39208403)
30. Lichtenberger, B.M., P.K. Tan, H. Niederleithner, N. Ferrara, P. Petzelbauer, and M. Sibilia. 2010. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 140:268-279. doi:10.1016/j.cell.2009.12.046
31. Lin, K.Y., M. Maricevich, N. Bardeesy, R. Weissleder, and U. Mahmood. 2008. In vivo quantitative microvasculature phenotype imaging of healthy and malignant tissues using a fiber-optic confocal laser microprobe. Transl. Oncol. 1:84-94.
32. Lu, W., H. Chen, F. Yel, F. Wang, and X. Xie. 2006. VEGF induces phosphorylation of STAT3 through binding VEGFR2 in ovarian carcinoma cells in vitro. Eur. J. Gynaecol. Oncol. 27:363-369.
33. MacDonald, T.T. 1992. Epithelial proliferation in response to gastrointestinal inflammation. Ann. N. Y. Acad. Sci. 664:202-209. doi:10.1111/j.1749-6632.1992.tb39761.x (Pubitemid 23022850)
34. Mor, F., F.J. Quintana, and I.R. Cohen. 2004. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J. Immunol. 172:4618-4623.
35. Mudter, J., L. Amoussina, M. Schenk, J. Yu, A. Brustle, B. Weigmann, R. Atreya, S. Wirtz, C. Becker, A. Hoffman, I. Atreya, S. Blesterfield, P.R. Galle, H. Lehr, S. Rose-John, C. Mueller, M. Lohoff, and M.F. Neurath. 2008. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118:2415-2428.
36. Neufert, C., C. Becker, and M.F. Neurath. 2007. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammationdriven tumor progression. Nat. Protoc. 2:1998-2004. doi:10.1038/nprot .2007.279
37. Neurath, M.F., B. Weigmann, S. Finotto, J. Glickman, E. Nieuwenhuis, H. Iijima, A. Mizoguchi, E. Mizoguchi, J. Mudter, P.R. Galle, A. Bhan, F. Autschbach, B.M. Sullivan, S.J. Szabo, L.H. Glimcher, and R.S. Blumberg. 2002. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195:1129-1143.
38. Pickert, G., C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H.-A. Lehr, S. Hirth, B. Weigmann, S. Wirtz, et al. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206:1465-1472. doi:10.1084/jem.20082683
39. Pitot, H.C. 1993. The molecular biology of carcinogenesis. Cancer. 72:962-970. doi:10.1002/1097-0142(19930801)72:3+<962::AIDCNCR2820721303>3. 0.CO;2-H
40. Popivanova, B.K., K. Kitamura, Y. Wu, T. Kondo, T. Kagaya, S. Kaneko, M. Oshima, C. Fujii, and N. Mukaida. 2008. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118:560-570.
41. Scaldaferri, F., S. Vetrano, M. Sans, V. Arena, G. Straface, E. Stigliano, A. Repici, A. Sturm, A. Malesci, J. Panes, et al. 2009. VEGF-A links angio- genesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 136:585-595: e5. doi:10.1053/j.gastro.2008.09.064
42. Semenza, G.L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-732. doi:10.1038/nrc1187
43. Senger, D.R., S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983-985. doi:10.1126/science.6823562
44. Seno, H., M. Oshima, T.O. Ishikawa, H. Oshima, K. Takaku, T. Chiba, S. Narumiya, and M.M. Taketo. 2002. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62:506-511.
45. Shibuya, M., and L. Claesson-Welsh. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312:549-560. doi:10.1016/j.yexcr.2005.11.012 (Pubitemid 43290332)
46. Stolfi, C., R. Pellegrini, E. Franze, F. Pallone, and G. Monteleone. 2008. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J. Gastroenterol. 14:4434-4439. doi:10.3748/wjg.14.4434
47. Strober, W., I.J. Fuss, and R.S. Blumberg. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20:495-549. doi:10.1146/annurev.immunol.20.100301.064816 (Pubitemid 34293433)
48. Wedam, S.B., J.A. Low, S.X. Yang, C.K. Chow, P. Choyke, D. Danforth, S.M. Hewitt, A. Berman, S.M. Steinberg, D.J. Liewehr, et al. 2006. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24:769-777. doi:10.1200/JCO.2005.03.4645 (Pubitemid 46622044)
49. Yao, J.S., W. Zhai, W.L. Young, and G.Y. Yang. 2006. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem. Biophys. Res. Commun. 342:1396-1404. doi:10.1016/j.bbrc.2006.02.100
50. Yoo, S.A., D.G. Bae, J.W. Ryoo, H.R. Kim, G.S. Park, C.S. Cho, C.B. Chae, and W.U. Kim. 2005. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J. Immunol. 174:5846-5855.
51. Yoo, S.A., S.K. Kwok, and W.U. Kim. 2008. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm. 2008:129873. doi:10.1155/2008/129873
52. Zisman, T.L., and D.T. Rubin. 2008. Colorectal cancer and dysplasia in inflammatory bowel disease. World J. Gastroenterol. 14:2662-2669. doi: 10.3748/wjg.14.2662